Tag Archives: Aalto Bio Reagents

June 2020—Aalto Bio Reagents announced the availability of its range of recombinant SARS-CoV-2 spike (S) proteins for diagnostic test manufacturers, vaccine developers, and researchers.

May 21, 2020—Aalto Bio Reagents announced the availability of its range of recombinant SARS-CoV-2 spike (S) proteins for diagnostic test manufacturers, vaccine developers, and researchers.

November 2016—Aalto Bio Reagents, a developer and provider of raw materials to the in vitro diagnostics industry and to research laboratories worldwide, announced the availability of its Tri-Plex suite of proteins and antibodies, which include its Zika Virus primary Envelope and NS1 proteins plus Chikungunya E2 wild type, E1 mutant, and E1 wild type proteins, and a complete set of Dengue virus proteins for serotypes 1–4.